WHO-GMP Certified Domestic Drug Manufacturers in Nepal: Current Status and Future Outlook

Ensuring the safety, efficacy, and quality of pharmaceutical products is crucial for public health. One of the internationally recognized standards for pharmaceutical manufacturing is WHO Good Manufacturing Practices (GMP). These guidelines ensure that drugs are consistently produced and controlled according to quality standards appropriate for their intended use. In Nepal, the adoption of WHO-GMP standards by domestic manufacturers is a key milestone in advancing pharmaceutical quality and industry credibility—both locally and globally.

List of WHO GMP Certified Pharmaceutical Companies in Nepal

Current Status – 62 WHO-GMP Certified Industries

As of May 2025, Nepal has 62 WHO-GMP certified pharmaceutical companies. This marks significant progress in improving regulatory compliance, production standards, and global acceptance of Nepali pharmaceutical products. These companies are now equipped to produce medicines that meet international standards, enabling them to expand exports and contribute to Nepal’s health security.

Registered Domestic Pharmaceutical Companies – 170 in 2025

Currently, there are 170 pharmaceutical companies registered in Nepal. This indicates that while the pharmaceutical industry is expanding, only around 36% (62 out of 170) have achieved WHO-GMP certification. This gap highlights the urgent need for investment in infrastructure, training, regulatory enforcement, and technical support to elevate the rest of the industry to international quality benchmarks.

Future Target – 100 WHO-GMP Certified by 2030

The Government of Nepal and the Department of Drug Administration (DDA) have set an ambitious yet achievable goal of having 100 domestic pharmaceutical industries WHO-GMP certified by 2030. This strategic objective aligns with the nation’s vision to:

Enhance public health through safe and effective medicines.
Boost the competitiveness of Nepali pharmaceuticals in global markets.
Attract foreign investment and technology transfer.
Promote Nepal as a regional hub for high-quality drug manufacturing.

Challenges and Opportunities

Challenges:

Limited technical expertise and regulatory capacity.
Infrastructure upgrades needed for smaller industries.
Financial constraints and cost of compliance.

Opportunities:

Strengthening public-private collaboration.
Government subsidies and incentives for GMP compliance.
International donor support and capacity-building programs.
Potential for regional export growth (SAARC, Southeast Asia, Africa).

Conclusion

The journey toward 100 WHO-GMP certified pharmaceutical industries by 2030 represents a crucial phase in Nepal’s pharmaceutical evolution. While the current progress is commendable, much work lies ahead to ensure that the entire domestic industry adheres to the highest standards of drug safety and quality. With coordinated efforts from the government, regulators, industry stakeholders, and international partners, Nepal is well-positioned to transform its pharmaceutical sector into a globally respected force.